Takeda's Anti-CD38 Therapy Mezagitamab Achieves 91% Response Rate in Immune Thrombocytopenia Phase II Trial
核心洞察
Mezagitamab, an anti-CD38 (搜索) monoclonal antibody, demonstrated a 91% platelet response rate in patients with immune thrombocytopenia (搜索) at the 600mg dose compared to 23% with placebo.
The Phase II trial enrolled 41 adults with chronic or persistent ITP (搜索) who had received an average of four prior treatments, addressing an unmet need for 20% of patients who don't benefit from current therapies.
The therapy showed rapid efficacy, normalizing platelet counts within 48 hours and improving quality of life, with a safety profile similar to placebo.
A Phase II clinical trial of Takeda (搜索)'s investigational anti-CD38 (搜索) therapy mezagitamab has demonstrated remarkable efficacy in treating immune thrombocytopenia (搜索) (ITP (搜索)), achieving a 91% platelet response rate at the highest tested dose. The results, published in the New England Journal of Medicine, offer new hope for patients with this challenging autoimmune disorder that affects platelet production and increases bleeding risk.
Trial Design and Patient Population
The Phase II study (NCT04278924) enrolled 41 adults across nine countries including Bulgaria, China, Croatia, Greece, Italy, Japan, Slovenia, Spain, and Ukraine. All participants had chronic or persistent ITP (搜索) lasting at least three months, with patients having received an average of four prior ITP treatments. The trial was designed as a dose-ranging, proof-of-concept study sponsored by Takeda Development Center Americas (搜索) and overseen by researchers at Mass General Brigham Cancer Institute (搜索).
Participants were initially randomized to receive subcutaneous injections of mezagitamab at doses of 100mg or 300mg, or placebo, administered once weekly for eight weeks. Following promising safety analysis results conducted during the trial, additional participants were assigned in a 2:1 ratio to receive either 600mg of mezagitamab or placebo.
Efficacy Results
The 600mg dose of mezagitamab demonstrated exceptional efficacy, triggering a platelet response in 10 out of 11 patients (91%) compared with three out of 13 patients (23%) in the combined placebo groups through week 16. The therapy showed rapid onset of action, with platelet counts normalizing within 48 hours of treatment initiation.
"This is a novel therapy that works fast and attacks the underlying mechanism of the disease," said lead author David J. Kuter, MD, DPhil, a hematologist with Mass General Brigham Cancer Institute (搜索). "We saw that it can have a rapid effect, normalizing platelet counts in 48 hours and improving quality of life."
Safety Profile
The safety analysis revealed that mezagitamab maintained a tolerability profile similar to placebo. During the trial, 19 out of 28 patients (68%) receiving mezagitamab experienced an adverse event, while nine of 13 patients (69%) in the placebo arm faced similar outcomes. Among patients experiencing adverse events, five (18%) in the mezagitamab group and three (23%) in the placebo group experienced Grade 3 or higher adverse events.
Mechanism of Action
Originally developed as a potential cancer treatment, mezagitamab is a monoclonal antibody that targets the CD38 (搜索) protein expressed on various immune cells, particularly plasma cells, natural killer cells, and certain T and B cells. The anti-CD38 therapy works by inhibiting these immune cells, addressing the underlying autoimmune mechanism that drives ITP (搜索).
Addressing Unmet Medical Need
The results are particularly significant given that approximately 20% of patients with ITP (搜索) do not benefit from currently available therapies. This substantial patient population represents a critical unmet medical need in the ITP treatment landscape, where targeted therapies have emerged in recent years but gaps remain.
Phase III Development
Following these positive Phase II results, Takeda (搜索) has initiated a Phase III trial (NCT06722235) to further evaluate mezagitamab in ITP (搜索). Mass General Brigham Cancer Institute (搜索) serves as the leading site in North America for this pivotal study. According to ClinicalTrials.gov, the company estimates primary completion of the Phase III trial by the end of 2027.
"This study was designed as a dose-ranging, proof-of-concept trial. We are now conducting a phase 3 clinical trial of 600-mg dose of mezagitamab with Mass General Brigham Cancer Institute (搜索) serving as the leading site in North America," Kuter noted.
Broader Development Program
Beyond ITP (搜索), Takeda (搜索) is exploring mezagitamab's potential in other autoimmune conditions. The company is evaluating the CD38 (搜索)-targeting antibody in a Phase III study for immunoglobulin A nephropathy (搜索) (IgAN (搜索)), following positive results from a Phase Ib open-label study (NCT05174221) that showed sustained positive impact on kidney function at 18 months.